Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2023-06-23 00:00:00 ET · period of report 2023-06-21 · accession 0001689375-23-000044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-06-23 | 2023-06-21 | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $15.01 | -17.5K | 28.0K | -38% | -$262.6K |
| D | 2023-06-23 | 2023-06-21 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +17.5K | 45.5K | +63% | +$36.8K |
| D | 2023-06-23 | 2023-06-21 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $0.00 | -17.5K | 83.4K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-21 | S | D | 8,593 | $14.84 | 36,864 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $15.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2023-06-21 | M | A | 17,500 | $2.10 | 45,457 | D | — | — | |
| 3 | Common | Common Stock | 2023-06-21 | S | D | 8,907 | $15.17 | 27,957 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-06-21 | M | D | 17,500 | $0.00 | 83,447 | D | $2.10 · — to 2030-11-10 | 17,500 Common Stock | (F4) 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. |